INmune Bio Announces Master Services Agreement With Uniphar For Named-Patient Access To Ebstrocel In Select European, MENA Markets
Share
Why It Matters
INmune Bio signed a deal to sell its medicine in Europe and the Middle East. When a small drug company finds partners to distribute its product, it shows the medicine may be real and useful.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.